Abstract: Cis ruthenium complexes that can be used as catalysts are described. The complexes are generally square pyramidal in nature, having two anionic ligands X adjacent to each other. The complexes can be used as catalysts, for example in olefin metathesis reactions. Corresponding trans ruthenium complexes are also described, together with cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand.

Abstract: Phase change ink comprising carrier and colorant of formula wherein Ra and Rb each, independently, are hydrogen, alkyl, including substituted and hetero-containing alkyl, aryl, including substituted and hetero-containing aryl, arylalkyl, including substituted and hetero-containing arylalkyl, or alkylaryl, including substituted and hetero-containing alkylaryl; R1 and R2 each, independently, are hydrogen, provided at least one of R1 and R2 is other than hydrogen, alkyl, including substituted and hetero-containing alkyl, aryl, including substituted and hetero-containing aryl, arylalkyl, including substituted and hetero-containing arylalkyl, or alkylaryl, including substituted and hetero-containing alkylaryl; R3, R4, R5, R6, and R7 each, independently, are alkyl, including substituted and hetero-containing alkyl, aryl, including substituted and hetero-containing aryl, arylalkyl, including substituted and hetero-containing arylalkyl, alkylaryl, including substituted and hetero-containing alkylaryl, or a substi

Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

Abstract: A process for producing an aldehyde compound of the invention comprising: reacting a compound represented by the following formula (a1) or (a2) with a hydrogen and a carbon monoxide in a presence of a compound containing a metal belonging to Groups 8 to 10 and a phosphorous compound so as to satisfy the following conditions (1) and (2) to synthesize an aldehyde compound; wherein the condition (1) is that a content of a metal included in the compound containing a metal belonging to Groups 8 to 10 is 0.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: A compound of the present invention comprises a triazapentalene backbone represented by the general formula 1 below as a fluorescent chromophore.

Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Abstract: A silane coupling agent is obtained from high-temperature heat distillation reaction of a silane coupling agent having a customary amic acid structure group. Dealcoholization reaction takes place between the carboxylic acid group and the alkoxysilyl group in the structure to induce intramolecular crosslinking. The crosslinked polymer component exerts a remarkable adhesion promoting effect.

Abstract: The present invention relates to a method for purifying a crude PNPNH compound by metalation and re-protonation.

Abstract: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.

Abstract: Process for the production of acetic acid and dimethyl ether by contacting methanol and methyl acetate with a catalyst composition at a temperature in the range 140 to 250 ° C. The catalyst composition contains a zeolite having a 2-dimensional channel system comprising at least one channel which has a 10-membered ring.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: A quantitative model that describes the assembly of diketopyrrolopyrrole-based donors and a perylenediimide acceptor into chiral superstructures, as a result of both hydrogen bonding and ?•••? stacking. This model provides thermodynamic parameters (?H° and ?S°) for all noncovalent interactions involved in the assembly and explains the subtle supramolecular cues that convert disordered aggregates into well-defined helical assemblies.

Abstract: A process for preparing a siloxane compound comprising a 2-hydroxyphenyl benzotriazole function which comprises at least one step in which a reaction for hydrosilylation of a compound 2-hydroxyphenyl benzotriazole comprising a substituent having a terminal double bond with a siloxane compound comprising an SiH function is carried out in the presence of a catalyst and of at least one volatile organic solvent corresponding to one of formula (VII) or (VIII). in which R4 and R5, which may be identical or different, represent a linear or branched C1-C4 alkyl radical, with the proviso that the sum of the carbons of R4 and R5 is less than or equal to 6; y is and integer between 1 and 3; R6 which may be identical or different, are linear or branched C1-C3 alkyl radicals, with the proviso that the sum of the carbons of R6 is less than or equal to 6 is disclosed.

Abstract: A method to produce D,L-Methionine from 2-hydroxy-4-(methylthio)butyronitrile by reaction with ammonia, optionally in the presence of carbon dioxide, is provided. The 2-hydroxy-4-(methylthio)butyronitrile is obtained by reaction of 3-methylmercaptopropionaldehyde with hydrogen cyanide in the presence of a base as catalyst in a main reaction zone of a multizone reactor. Residual gaseous hydrogen cyanide is removed from the main reaction zone to an absorption and post-reaction zone of the reactor which comprises a mixture of 3-methylmercaptopropionaldehyde and the catalyst; and the gaseous hydrogen cyanide is further reacted with the 3-methylmercaptopropionaldehyde in the absorption and post reaction zone. A molar ratio of hydrogen cyanide to 3-(methylthio)propanal in the main reaction zone is from 0.98 to 1.03.

Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.

Abstract: The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.

Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.